Akeso, Inc. (09926.HK), established in 2012, is a pioneer in the research and development of original antibody drugs in China and one of the representative enterprises of China’s drug innovation in the new era. Founded by a team of scientists with rich experience in international drug development, the Company focuses on the unmet clinical needs worldwide in major diseases, such as cancer, autoimmune diseases, inflammation and metabolic diseases, and is dedicated to the research, development, manufacturing and commercialization of innovative biologics that are affordable to patients worldwide.

The Company has successfully promoted the commercialization of two innovative biological drugs that are first-in-class and best-in-class, including the first-in-class tumor immunotherapeutic new drug开坦尼^® (PD-1/CTLA-4 bi-specific antibody, Cadonilimab injection) and innovative drug安尼可^® (PD-1 monoclonal antibody, Penpulimab injection) developed by Akeso. 开坦尼^® is the world’s first tumor dual immune checkpoint inhibitor bi-specific antibody approved for marketing.

Since its establishment, the Company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (TETRABODY) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Based on this, we have developed more than 30 innovative drug candidates with full independent intellectual property rights, including six bi-specific antibody drugs. Among them, more than 80 clinical trials of 15 drug candidates have been initiated in China, the United States, Australia and New Zealand. The Company has also become one of the innovative antibody drug R&D enterprises with the richest pipelines under research in China.

We have developed a proprietary “TETRABODY” technology platform for the design and manufacture of innovative tetravalent bi-specific antibodies. It overcomes CMC challenges such as low expression levels due to the high molecular weight of bi-specific antibodies, process development obstacles due to the structural heterogeneity of bi-specific antibodies, and non-druggability due to the lack of stability of bi-specific antibodies. At present, Akeso is leading the world in the development of new bi-specific antibody drugs PD-1/CTLA-4 and PD-1/VEGF.

Through efficient and breakthrough R&D innovation, we always integrate the global superior resources, develop the first-in-class and best-in-class new drugs, provide affordable therapeutic antibodies for patients worldwide, and continuously create more commercial and social values so as to become a global leading biopharmaceutical enterprise.